DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-812/S-001

Pfizer Consumer Healthcare
Attention: John R. Jacobs
V.P. Global Regulatory Affairs
201 Tabor Road
Morris Plains, NJ 07950

Dear Mr. Jacobs:

Please refer to your supplemental new drug application dated March 8, 2006, received March 9, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Men's Rogaine Foam (5% minoxidil) Topical Aerosol.

We acknowledge receipt of your submission dated April 11, 2006.

This supplemental new drug application provided labeling for a Men's Rogaine Foam fragranced product.

We have completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text.

We remind you to remove the word "New" from the label after 6 months of OTC marketing.

The final printed labeling (FPL) must be identical to the submitted labeling (carton and immediate container submitted March 9, 2006, and package insert submitted April 11, 2006), and must be formatted in accordance with the requirements of 21 CFR 201.66.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-812/S-001**." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call LCDR Keith Olin, Regulatory Project Manager, at (301) 796-0961.

Sincerely,

{See appended electronic signature page}

Andrea Leonard-Segal, MD
Director
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Andrea Segal

5/22/2006 07:44:22 AM